Pfizer Inc. (PFE) Quick Ratio (Acid-Test): 0.87
Is Pfizer Inc.’s quick ratio (acid-test) high or low?
Pfizer Inc.'s quick ratio (acid-test) of 0.87 is in line with its 5-year average of 0.95, around the middle of its 5-year range (0.69–1.19).
As of Thursday, June 11, 2026. 2.79% below its 12-month average of 0.90.
PFE Quick Ratio (Acid-Test) Chart
PFE Average Quick Ratio (Acid-Test) Chart
PFE Current vs Average Quick Ratio (Acid-Test) Chart
PFE Quick Ratio (Acid-Test) Metrics
QUICK RATIO (ACID-TEST)
0.87
QUICK RATIO (ACID-TEST) AVG TTM
0.90
QUICK RATIO (ACID-TEST) AVG 3Y
0.87
QUICK RATIO (ACID-TEST) AVG 5Y
0.95
QUICK RATIO (ACID-TEST) AVG 10Y
1.01
QUICK RATIO (ACID-TEST) AVG 15Y
1.32
QUICK RATIO (ACID-TEST) AVG 20Y
1.38
CURRENT VS TTM AVG
-2.79%
CURRENT VS 3Y AVG
+0.00%
CURRENT VS 5Y AVG
-8.58%
CURRENT VS 10Y AVG
-13.71%
CURRENT VS 15Y AVG
-34.15%
CURRENT VS 20Y AVG
-36.91%
PFE Competitors' Quick Ratio (Acid-Test)
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $149.61B | 0.87 | 0.90 | 0.87 | 0.95 |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 3.96 | 3.59 | 3.74 | 4.30 |
| Abbott Laboratories (ABT) | $155.75B | 1.18 | 1.21 | 1.20 | 1.26 |
| Gilead Sciences, Inc. (GILD) | $156.35B | 1.31 | 1.38 | 1.29 | 1.26 |
| CVS Health Corporation (CVS) | $126.70B | 0.63 | 0.61 | 0.63 | 0.63 |
| Danaher Corporation (DHR) | $126.39B | 1.51 | 1.28 | 1.37 | 1.36 |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 1.53 | 1.41 | 1.34 | 1.37 |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 1.14 | 1.15 | 1.19 | 1.27 |
| Amgen Inc. (AMGN) | $188.37B | 0.90 | 0.93 | 1.02 | 1.14 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 2.46 | 2.41 | 3.31 | 3.62 |
Liquidity Comparison
Quick Ratio
0.87
Excludes inventory
Current Ratio
1.16
Includes inventory
Pfizer Inc. Quick Ratio (Acid-Test) Formula & Definition
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Quick Ratio (Acid-Test) FAQ
- What is the quick ratio (acid-test) for Pfizer Inc. (PFE)?
- The quick ratio (acid-test) for PFE stock is 0.87.
- Is Pfizer Inc.'s quick ratio (acid-test) high or low?
- Pfizer Inc.'s quick ratio (acid-test) of 0.87 is in line with its 5-year average of 0.95, around the middle of its 5-year range (0.69–1.19).
- What is the TTM average quick ratio (acid-test) for Pfizer Inc. (PFE)?
- The TTM average quick ratio (acid-test) for PFE stock is 0.90.
- What is the 3Y average quick ratio (acid-test) for Pfizer Inc. (PFE)?
- The 3Y average quick ratio (acid-test) for PFE stock is 0.87.
- What is the 5Y average quick ratio (acid-test) for Pfizer Inc. (PFE)?
- The 5Y average quick ratio (acid-test) for PFE stock is 0.95.
- What is the 10Y average quick ratio (acid-test) for Pfizer Inc. (PFE)?
- The 10Y average quick ratio (acid-test) for PFE stock is 1.01.
- What is the 15Y average quick ratio (acid-test) for Pfizer Inc. (PFE)?
- The 15Y average quick ratio (acid-test) for PFE stock is 1.32.
- What is the 20Y average quick ratio (acid-test) for Pfizer Inc. (PFE)?
- The 20Y average quick ratio (acid-test) for PFE stock is 1.38.
Pfizer Inc. Quick Ratio (Acid-Test) History
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2025-12-31 | 0.87 |
| 2024-12-31 | 0.92 |
| 2023-12-31 | 0.69 |
| 2022-12-31 | 1.00 |
| 2021-12-31 | 1.19 |
| 2020-12-31 | 1.04 |
| 2019-12-31 | 0.69 |
| 2018-12-31 | 1.33 |
| 2017-12-31 | 1.10 |
| 2016-12-31 | 1.03 |
| 2015-12-31 | 1.23 |
| 2014-12-31 | 2.41 |
| 2013-12-31 | 2.14 |
| 2012-12-31 | 1.90 |
| 2011-12-31 | 1.78 |
| 2010-12-31 | 1.82 |
| 2009-12-31 | 1.32 |
| 2008-12-31 | 1.43 |
| 2007-12-31 | 1.90 |
| 2006-12-31 | 1.91 |
| 2005-12-31 | 1.26 |
| 2004-12-31 | 1.25 |
| 2003-12-31 | 1.01 |
| 2002-12-31 | 1.19 |
| 2001-12-31 | 1.15 |
| 2000-12-31 | 1.21 |
| 1999-12-31 | 1.04 |
| 1998-12-31 | 1.13 |
| 1997-12-31 | 0.95 |
| 1996-12-31 | 0.87 |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla